Giannatempo, P., Galsky, M. D., Duran, I., Boni, V., Necchi, A., Italiano, A., McKean, M., Verlingue, L., Balaraman, R., DeMars, L. R., Josephs, K., Xu, C., Torras, O. R. (2025). Phase 1/2 Duravelo-1 study: Preliminary results of nectin-4–targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4567